|Bid||150.62 x 1000|
|Ask||150.82 x 900|
|Day's Range||150.48 - 151.60|
|52 Week Range||90.64 - 151.60|
|Beta (3Y Monthly)||0.41|
|PE Ratio (TTM)||51.93|
|Forward Dividend & Yield||1.56 (1.04%)|
|1y Target Est||N/A|
Patients with chronic obstructive pulmonary disease (COPD) at Louisville’s JenCare Senior Medical Center, a ChenMed company, saw their health outcomes improve significantly when their primary care physicians (PCPs) encouraged using Propeller’s digital health tool to manage their COPD, reports new research by Propeller Health, JenCare, ChenMed, and the Center for Healthy Air, Water and Soil investigators published in JMIR Formative Research.
With the expansion of the My Pharmacy feature, patients can use Propeller to refill prescriptions with five of the seven largest pharmaceutical providers in the U.S. Propeller Health, a leading digital health company dedicated to the management of asthma and chronic obstructive pulmonary disease (COPD), today announced that users are now able to access pharmacy services from CVS, Walmart, Kroger and Rite-Aid directly from the Propeller app. In January 2019, Propeller announced the launch of My Pharmacy, an in-app feature that allows users to manage their prescription refills for asthma and COPD and locate a nearby pharmacy from the Propeller app.
ResMed today announced that Rob Douglas, chief operating officer, will present at the Credit Suisse 28th Annual Healthcare Conference on Tuesday, November 12, 2019, beginning at approximately 9:10 a.m.
Starting today, Propeller users will be able to “ring” the sensor on a misplaced inhaler to make it easier to find, through an update to the Find My Inhaler feature in the Propeller app. Propeller is a digital health tool that helps people with asthma or COPD manage their breathing. Propeller sensors connect to patients’ existing inhalers and transmit data on medication use and health patterns to the Propeller app on patients’ smartphones.
SAN DIEGO-- -- Year-over-year revenue grows 16%, non-GAAP operating profit up 22% Balanced growth across product portfolio and global markets Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com ResMed Inc. , a world-leading connected health company, today announced results for its quarter ended September 30, 2019. First Quarter 2020 Highlights ...
ResMed (RMD) (RMD.AX) today introduced AirFit N30, the world’s first tube-down nasal cradle CPAP mask with a front-facing tube – a brand-new option for sleep apnea treatment. ResMed’s lightest mask yet, AirFit N30 features an adjustable elastic headgear, plus a nasal cradle cushion that sits under the nasal bridge, eliminating soreness in that area. Together, these innovations help make starting and staying on CPAP therapy easier than ever for more of the 936 million people worldwide living with sleep apnea.
The survey highlights a reason for optimism that the markets for digital health technology will only continue to grow. The survey of a nationally representative sample of 3,000 Americans, conducted in partnership with Edelman Intelligence, revealed that the use of – and confidence in – remote digital health technology is widespread: 56% of those surveyed currently monitor their health with at least one digital data collection tool. Perhaps more surprising, remote digital health technology seems to have deepened people’s connection with their physicians rather than distanced them from one another.
Cerner Corporation (CERN), a global health platform and innovation company, and ResMed (NYSE: RMD, ASX: RMD), a world-leading digital health company, today announced a new collaboration agreement to help providers make more informed treatment decisions, control costs and deliver seamless care across health systems to the home. To address this trend, Cerner designated ResMed’s Brightree Home Health and Hospice platform as its preferred solution in the space to integrate with its Cerner Millennium® electronic health record (EHR).
ResMed today announced it plans to release financial and operational results for the first quarter of fiscal year 2020 on Thursday, October 24, 2019, after the New York Stock Exchange closes.
MatrixCare announced today that Dheeraj Mahajan, MD, MBA, MPH, FACP, CMD, CIC, CHCQM, has joined its team as chief medical officer and executive vice president to advance MatrixCare’s vision of creating a seamless continuum where data moves with the patient, connecting both acute and post-acute care providers. Dr. Mahajan joins MatrixCare with more than 15 years as a practicing physician and is a nationally recognized expert and speaker on physician payment models, clinical documentation improvement, denial management, quality measurement in post-acute and long-term care, and transitional care quality improvement.
NEWPORT BEACH, Calif., July 15, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.
ResMed (RMD) (RMD.AX) revealed roughly 170 million people across North and South America have sleep apnea, according to a study it presented at the annual SLEEP meeting hosted by the American Academy of Sleep Medicine (AASM) and the Sleep Research Society.
ResMed, a world leader in connected health solutions for sleep apnea, lung disease, and other chronic diseases, today announced the appointment of Shubhi Khurana as general manager for India and South Asia.
ResMed today announced that Rob Douglas, president and chief operating officer, will participate in a fireside chat discussion at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2019, beginning at approximately 10:00 a.m.
ResMed today announced that Mick Farrell, chief executive officer, will present at the 39th Annual William Blair Growth Stock Conference on Thursday, June 6, 2019, beginning at approximately 8:40 a.m.
.@ResMed study finds #CPAP adherence improved by remote monitoring, self-monitoring across 3 countries
Age, gender, and disease severity all impact long-term #CPAP adherence more than previously thought, according to a million-patient study shown at #ATS2019 #sleepapnea
ResMed (NYSE: RMD, ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital SaaS solutions, today announced it has elected experienced business executive Jan De Witte to its board of directors. Mr. De Witte was appointed during ResMed’s regularly scheduled board meeting on May 16, 2019, to fill a newly created directorship, effective immediately.